Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 217

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 217
---
1.0% of the outstanding shares of our common stock. |

| 123 |

| (1) | The shares of our common stock beneficially owned by the Selling Stockholder prior to this offering represents                                
 the 131,909 shares of common stock that we issued to Yorkville on October 24, 2025 as Commitment Shares in partial consideration for entering 
 into the SEPA with us on October 24, 2025, but excludes the Conversion Shares into which the Convertible Notes (which upon issuance are       
 immediately convertible into common stock) may be converted by the Selling Stockholder at any time, subject to the Exchange Cap (for so       
 long as it continues to apply) and the Beneficial Ownership Limitation as set forth in the Convertible Notes. In accordance with Rule         
 13d-3(d) under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the Advance       
 Shares that Yorkville may be required to purchase under the SEPA, because the issuance of such shares is solely at our discretion and         
 is subject to conditions contained in the SEPA, the satisfaction of which are entirely outside of Yorkville’s control, including              
 the Registration Statement that includes this prospectus becoming and remaining effective. Furthermore, the Advance Shares under the SEPA     
 are subject to certain agreed upon maximum amount limitations set forth in the SEPA. As of the date of this prospectus, both the Convertible  
 Notes and the SEPA contain provisions that prohibit us from issuing and selling any Advance Shares under the SEPA or issuing Conversion       
 Shares upon conversion of the Convertible Notes to Yorkville, in the aggregate, in excess of the 19.99% Exchange Cap, unless and until        
 we obtain stockholder approval to do so (which stockholder approval we are seeking to obtain from our stockholders at the upcoming 2025       
 Annual Meeting of Stockholders to be convened on December 19, 2025). Furthermore, as of the date of this prospectus, both the SEPA and        
 the Convertible Notes prohibit us from issuing and selling any Advance Shares under the SEPA or issuing Conversion Shares upon conversion     
 of the Convertible Notes to Yorkville, to the extent such Advance Shares and/or Conversion Shares (as applicable), when aggregated with       
 all other shares of our common stock then beneficially owned by Yorkville would cause Yorkville’s beneficial ownership of our common          
 stock to exceed the 4.99% Beneficial Ownership Limitation.